Pre-procedural platelet reactivity after clopidogrel loading in korean patients undergoing scheduled percutaneous

Min-Kyung Kang1, Young-Hoon Jeong, Seong-Eun Yoon

  • 1Division of Cardiology, Department of Internal Medicine, Gyeongsang National University Hospital, Jinju, Korea.

Insights

Korean patients often have high post-clopidogrel platelet reactivity (HPPR) due to CYP2C19 variant alleles. A standard loading dose of clopidogrel is insufficient for adequate platelet inhibition in these patients.

Area of Science:

  • Pharmacogenomics
  • Cardiovascular Medicine
  • Clinical Pharmacology

Background:

  • CYP2C19 variant alleles (*2 and *3) are more prevalent in Korean populations, potentially affecting antiplatelet drug efficacy.
  • Pre-procedural platelet reactivity (PR) can influence outcomes in patients undergoing percutaneous coronary intervention (PCI).

Purpose of the Study:

  • To investigate the level of PR and the prevalence of high post-clopidogrel platelet reactivity (HPPR) in Korean patients receiving a standard loading dose (LD) of clopidogrel.
  • To assess the impact of CYP2C19 genotype on PR and HPPR in this patient cohort.

Main Methods:

  • 215 Korean patients undergoing scheduled PCI had their PR assessed 12-24 hours after a 300-mg clopidogrel LD.
  • Platelet reactivity was measured using conventional aggregometry and VerifyNow, with HPPR defined as >50% maximal PR at 5 µmol/L ADP.
  • CYP2C19 genotyping was performed on 176 patients.

Main Results:

  • The prevalence of HPPR was 52.1% based on ADP-induced maximal PR >50% at 5 µmol/L.
  • High P2Y₁₂ reaction units (PRU ≥240) were observed in 69.8% of patients.
  • Carriage of CYP2C19 variant alleles (*2 or *3) was a significant predictor of HPPR (OR 4.202, p<0.001).

Conclusions:

  • A 300-mg loading dose of clopidogrel does not achieve adequate pre-procedural platelet inhibition in Korean patients undergoing scheduled PCI.
  • The higher prevalence of CYP2C19 mutant alleles in Korean patients is associated with increased HPPR.
  • These findings suggest potential genotype-guided antiplatelet therapy strategies may be warranted.
Abstract

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Cardiac Catheterization I: Pre-Procedure Overview01:28

Cardiac Catheterization I: Pre-Procedure Overview

Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...